前胃泌素释放肽和前降钙素作为甲状腺髓样癌诊断检查中的附加标志物
该研究前瞻性纳入荷兰三级中心2013至2025年因甲状腺结节性疾病接受手术的成人患者(发现队列335例,验证队列61例来自瑞士),评估降钙素(CT)、前降钙素(PCT)、前胃泌素释放肽(proGRP)和癌胚抗原的诊断性能。结果显示proGRP单独或联合CT无附加价值,而CT联合PCT两步法在CT 10-100 pg/mL范围诊断准确性高。
要点
- proGRP单独或联合CT对MTC诊断无附加价值。
- CT联合PCT两步法在CT 10-100 pg/mL时敏感性100%、特异性99.7%。
- PCT诊断性能与CT相似,proGRP敏感性较低(69.2%)。
核心结论
- proGRP单独或联合CT对MTC诊断无附加价值;CT联合PCT两步法在CT 10-100 pg/mL范围是诊断MTC的有前景方法,诊断准确性高。
研究设计与样本
- 前瞻性多队列研究,发现队列来自荷兰三级中心2013至2025年因甲状腺结节性疾病接受手术的成人患者335例,验证队列来自瑞士61例。
- 术前采集血清样本,分别计算CT、PCT、proGRP和癌胚抗原的诊断性能,并研究联合不同标志物的两步法。
主要发现
- 发现队列和验证队列分别335例和61例;患者包括良性疾病166例、其他甲状腺癌(非MTC)186例和MTC 44例。
- MTC中proGRP和PCT中位水平显著高于良性疾病和非MTC。
- proGRP敏感性低(69.2% [CI 48.2-85.7]),PCT与CT性能相似(敏感性分别为100.0% [CI 89.1-100.0]和100.0% [CI 88.8-100.0])。
- CT联合PCT在单个队列和合并队列中诊断性能最佳,敏感性100% [CI 91.8-100.0],阴性预测值100% [CI 98.9-100.0],特异性99.7% [CI 98.4-100.0],阳性预测值97.7% [CI 88.0-99.9]。
临床怎么用
- 作者认为,在CT浓度10-100 pg/mL范围内,联合检测CT和PCT的两步法可用于诊断甲状腺结节患者的MTC,诊断准确性高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Calcitonin (CT), a well-established tumor marker for medullary thyroid carcinoma (MTC), is limited by a high rate of false positives in the diagnostic phase. Potential new markers for MTC are procalcitonin (PCT) and progastrin-releasing peptide (proGRP). Where literature has proven noninferiority for PCT, evidence is lacking for proGRP. Therefore, the present study prospectively evaluated the clinical performance of proGRP and PCT in a multicohort study of patients with MTC compared with other thyroid diseases. Methods: Adult patients undergoing thyroid surgery for thyroid nodular disease diagnosed in a tertiary center from the Netherlands (discovery cohort) between 2013 and 2025 were prospectively included. Serum samples were collected preoperatively. Diagnostic performance of CT, PCT, proGRP, and carcinoembryonic antigen was calculated separately. A two-step approach, combining different markers, was investigated. Analyses were repeated in a validation cohort from Switzerland. Results: The discovery and validation cohorts consisted of 335 and 61 patients, respectively. Patients had benign disease (n = 166), other thyroid carcinomas (non-MTC, n = 186), or MTC (n = 44). Median proGRP and PCT levels were significantly higher in MTC compared with benign disease and non-MTC. ProGRP had a low sensitivity (69.2% [CI 48.2-85.7]), while PCT performed similarly to CT (100.0% [CI 89.1-100.0] and 100.0% [CI 88.8-100.0], respectively). The combination of CT and PCT, both in the individual cohorts and when combining the two cohorts, showed the best diagnostic performance with a sensitivity of 100% [CI 91.8-100.0] and negative predictive value of 100% [CI 98.9-100.0] and specificity and positive predictive value of 99.7% [CI 98.4-100.0] and 97.7% [CI 88.0-99.9], respectively. Conclusions: ProGRP alone or with CT does not have additional value as a diagnostic marker for MTC. A two-step approach combining the use of CT and PCT measurement, in the CT concentration range between 10 and 100 pg/mL, is a promising method to diagnose MTC in patients with thyroid nodules with high diagnostic accuracy.
引用
- Schonebaum LE, van den Berg SAA, van Balkum M, et al. Progastrin-Releasing Peptide and Procalcitonin as Additional Markers in the Diagnostic Workup for Medullary Thyroid Carcinoma. Thyroid. 2025. PMID: 40576708. doi:10.1089/thy.2024.0293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。